CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 89 enrolled
Drug / intervention
bimatoprost ophthalmic 0.03% solution +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00958035
NCT00958035Phase 4Completed
CompareCT.gov

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Allergan·interventional·Posted Aug 13, 2009·Updated Jan 5, 2012

In Brief

A Phase 4 clinical trial evaluating bimatoprost ophthalmic 0.03% solution and vehicle sterile solution (placebo) for Hypotrichosis. Completed, enrolled 89 participants across 1 site.

Detailed Summary

This study will evaluate the safety and efficacy of bimatoprost solution 0.03% once daily to the upper eyelid margins (where the eyelashes meet the skin) compared with vehicle in increasing overall eyelash prominence in self-identified African American/ethnic black subjects exhibiting hypotrichosis of the eyelashes (inadequate or not enough eyelashes).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypotrichosis
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 13, 2009
Enrollment StartNov 1, 2009
Primary CompletionJul 1, 2010
Study CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 16.9 years ago

Interventions

bimatoprost ophthalmic 0.03% solutiondrug

Apply one drop of study medication along the upper eyelid margin once daily in the evening

vehicle sterile solution (placebo)drug

Apply one drop of study medication along the upper eyelid margin once daily in the evening